Press Release Headlines

Kibow Biotech Joins with Apollo Hospital Group to Celebrate Dr. Eli Friedman and His Contribution to the Field of Nephrology with Lifetime Achievement Award

NEWTOWN SQUARE, Pa., March 14, 2014 /PRNewswire/ — Kibow Biotech is pleased to announce that March 13, on the occasion of World Kidney Day (, it joined with Apollo Hospital Group (Chennai, India) to honor Dr. Eli A. Friedman, M.D., M.A.C.P., F.A.C.P., with a Lifetime Achievement Award, celebrating his excellence and contribution to the field of nephrology for over five decades, as well as his unbroken record of humanitarianism, impeccable bedside manner, sharp wit and acumen, professionalism, friendship, love, and care.

Dr. Eli A. Friedman, a Brooklyn native, gave much effort and many years of his life to serving the nephrology patients and the students as a Distinguished Teaching Professor of Medicine at the State University of New York's Downstate Medical Center, Brooklyn, New York.

After receiving his medical doctor's degree at the Downstate Medical Center, Dr. Friedman spent four years at Harvard's Peter Ben Brigham Hospital as intern, resident, and nephrology fellow, gaining knowledge in what was at the time new specialty of nephrology and transplant immunology. As a Lieutenant Commander in the U.S. Public Health Service (PHS), Dr. Friedman was recruited to the Communicable Disease Center's Epidemic Intelligence Service based in Atlanta, GA, with an appointment as Assistant Professor of Medicine at Emory University's College of Medicine.

In 1963, Dr. Friedman returned to Downstate Medical Center as Assistant Professor of Medicine, where he established the first in the U.S. federally funded hemodialysis center linked to a kidney transplant facility. His hemodialysis patients at Kings County Hospital formed the American Association of Kidney Patients, where he served as Medical Advisory Board Chair. He has also served as president of the American and International Societies for Artificial Organs, and received honorary membership from kidney societies in Belgium, Germany, India, Italy, Japan, Taiwan, and Yugoslavia.

In 2003, Dr. Friedman was elected President of the International Society for Geriatric Nephrology and Urology. Author of 530 scientific publications, including editing 11 books, Dr. Friedman's concern for medical ethics leading to Chairing Downstate's Institutional Review Board for over a decade, was fueled by the stress imposed by the need to apply selection criteria to patients who would be offered life prolongation by hemodialysis prior to its funding in 1972 by the U.S. PHS.

Research interests pursued by Dr. Friedman focused on both slowing the course of progressive chronic kidney disease (CKD) and easing patient adjustment to the burden of irreversible kidney failure during its major therapies of hemodialysis and kidney transplantation. He designed an artificial kidney within an attache case simplifying travel for dialysis patients.

More recently, Dr. Friedman interests centered on the possible application of orally ingested probiotic bacteria as therapy for kidney failure without the need for dialysis. Dr. Friedman has served as a pro bono Chairman of Kibow Biotech's Scientific Advisory Board since the very inception of the company, and has been its most steadfast champion, albeit an invariably tough, constructively critical, and ethically scrupulous one.

Words cannot express the extent of fondness and gratitude that Dr. Natarajan Ranganathan of Kibow Biotech and Dr. Prathap C. Reddy of Apollo Hospitals feel toward Dr. Friedman. They are proud to call him not just a professional colleague, but a personal friend, and to recognize his lifelong contribution to the field of nephrology with a joint Lifetime Achievement Award on World Kidney Day 2014.

About Kibow Biotech: Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

For further information, contact:
Natarajan Ranganathan, PhD
Managing Director
1 (610) 353-5130